https://www.pharmaceutical-technology.com/news/mei-kyowa-kirin-zandelisib/
MEI Pharma and Kyowa Kirin have plans to discontinue the international development of zandelisib for B-cell malignancies outside of Japan.
kyowa kirinmeidiscontinuedevelopingzandelisib
https://www.biospace.com/mei-pharma-and-kyowa-kirin-announce-data-from-the-ongoing-global-phase-2-tidal-study-evaluating-zandelisib-as-a-single-agent-in-patients-with-relapsed-or-refractory-follicular-lymphoma
MEI Pharma, Inc. today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma.
kyowa kirinmeipharmaannouncedata
https://www.avanade.com/en-us/insights/clients/kyowa-kirin-international
Avanade partnered with KKI to modernize its data infrastructure using Microsoft Azure and Databricks, enabling modern-day data integration and empowering...
kyowa kirinclient storyunited statesinternationalavanade
https://www.pharmaceutical-technology.com/data-insights/rocatinlimab-kyowa-kirin-atopic-dermatitis-atopic-eczema-likelihood-of-approval/
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Atopic Dermatitis (Atopic Eczema).
kyowa kirinatopic dermatitiseczemalikelihood
https://www.pharmaceutical-technology.com/data-insights/tivozanib-kyowa-kirin-diabetic-macular-edema-likelihood-of-approval/
Tivozanib is under clinical development by Kyowa Kirin and currently in Phase II for Diabetic Macular Edema.
diabetic macular edemakyowa kirintivozaniblikelihood